Venetoclax, a small molecule BH3-mimic, inhibits BCL-2, forcing cells into programmed cell death and is prescribed for elderly, newly diagnosed or relapsed/refractory AML. This evidence concerns the gene BCL2 and acute myeloid leukemia.